Navigation Links
Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study
Date:5/17/2011

By Serena Gordon
HealthDay Reporter

TUESDAY, May 17 (HealthDay News) -- Newer epilepsy medications don't increase the risk of major birth defects in women taking these drugs during the first trimester of pregnancy, according to new research.

But because the drugs are relatively new, further studies are needed to get a clearer picture of their safety profile, experts said.

In a large study of children born in Denmark, including those exposed to newer anti-epileptic drugs, researchers found the rate of major birth defects was 3.2 percent for babies born to women taking the epilepsy medications and 2.4 percent for women not taking these drugs.

"In a nationwide Danish study of more than 800,000 births, we found no support for an increased risk of birth defects following use of newer generation anti-epileptics in early pregnancy," said the study's lead author, Ditte Molgaard-Nielsen, an epidemiologist at Statens Serum Institute in Copenhagen.

"Pregnant women and women planning pregnancy can be reassured that our study and current knowledge of the safety of newer generation anti-epileptics does not provide cause for concern with respect to birth defect risk," she added.

Results of the study were published in the May 18 issue of the Journal of the American Medical Association.

Between 0.2 percent and 0.5 percent of pregnant women take anti-epileptic medications during pregnancy, according to background information in the study. Most women who take these medications do so to control seizures, but sometimes the drugs are prescribed for bipolar mood disorders, migraines and nerve pain disorders, the study authors noted.

When used during pregnancy, older epilepsy medications -- such as phenobarbital, phenytoin, valproate and carbamazepine -- have been linked to as much as a three-fold higher risk of birth defects, according to the study.

The difficulty in managing women with epilepsy during pregnancy is that treatment needs to be individualized, and not all women respond to all treatments. In many cases, it takes more than one medication to control seizures. And, uncontrolled epilepsy can also cause harm to a fetus, according to Dr. Loralei Thornburg, a maternal-fetal medicine specialist at the University of Rochester's Strong Memorial Hospital in New York, who was not involved with the study.

Medication options for women with epilepsy increased in the 1990s, but because these drugs are relatively new, little information has been available about their potential risk in pregnant women, the authors of the new study pointed out.

For the current study, Molgaard-Nielsen and a colleague reviewed data on all live births in Denmark from January 1996 through September 2008. The study included a total of 837,795 live births, including 1,532 babies who were exposed to newer epilepsy medications during the first trimester of pregnancy.

In the group of babies exposed to newer medications, such as lamotrigine, oxcarbazepine, topiramate, gabapentin and levetiracetam, 49 (3.2 percent) were diagnosed with major birth defects. In the large group of babies who weren't exposed to epilepsy medications, 19,911 babies (2.4 percent) were diagnosed with a major birth defect, according to the report.

Although the overall rates of birth defects were low, the study authors found that babies exposed to topiramate had 44 percent higher odds of having a birth defect, while babies exposed to lamotrigine during the first trimester of pregnancy had 18 percent higher odds of a birth defect. Those exposed to oxcarbazepine had 14 percent lower odds of a birth defect, the results showed.

There weren't enough women taking gabapentin or levetiracetam to estimate whether or not these medications are associated with increased odds of birth defects, the study authors noted.

"The management of epilepsy is complicated and challenging, and should be directed by experienced clinicians taking into account a wide range of factors, not just birth defect risks. These adverse effects include preterm birth, low birth weight, fetal death and adverse effects experienced by the mother," said Molgaard-Nielsen.

Still, Molgaard-Nielsen added: "Further studies investigating newer-generation anti-epileptic drugs and the risk of adverse effects other than birth defects are needed to provide a more complete picture of the risks and benefits of different anti-epileptics."

Thornburg added: "This is the best evidence we have thus far to say these drugs are safer than previous medications. Are they absolutely safe? I don't think anyone can say that about any medication, but it's about what's the best choice."

More information

Learn more about epilepsy and pregnancy from the Epilepsy Foundation.

SOURCES: Ditte Molgaard-Nielsen, M.Sc., epidemiologist, Statens Serum Institute, Copenhagen, Denmark; Loralei Thornburg, M.D., assistant professor, obstetrics and gynecology, University of Rochester School of Medicine and Dentistry, and maternal-fetal medicine specialist, Strong Memorial Hospital, Rochester, N.Y.; May 18, 2011, Journal of the American Medical Association


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Newer Pill Linked to Higher Risk of Blood Clots
2. Newer Versions of the Pill Pose No Added Risk to Gallbladder
3. UCSF analysis shows newer surgery for neck pain may be better
4. Newer antimalarials more effective than quinine against severe malaria
5. Research shows rapid adoption of newer, more expensive prostate cancer treatments
6. Newer Drug May Help Prevent Fracture in Men With Prostate Cancer
7. Newer, more intense chemotherapy with less radiation not more effective against Hodgkins lymphoma
8. Decrease in suicide not linked to newer antidepressants
9. Newer Drugs Beat Gleevec in Head-to-Head Trials
10. In infant heart surgery, newer technique yields better survival in first year of life
11. Newer Genetic Info Adds Little to Predicting Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Newer Epilepsy Meds Less Likely to Cause Birth Defects: Study
(Date:10/13/2017)... ... October 13, 2017 , ... Dickinson Insurance and Financial ... financial preparation services, is providing an update on a charitable event that began ... Rescue is a locally recognized nonprofit that provides shelter and care for animals ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board ... Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will ... Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of President ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Hannah Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical ... the primary prevention of cardiovascular diseases during the 15th Annual Women’s Health ...
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... ... 2017 , ... Global Healthcare Management’s 4th Annual Kids Fun Run brought out ... free event, sponsored by Global Healthcare Management’s CEO, Jon Letko, is aimed at getting ... children of all ages; it is a non-competitive, non-timed event, which is all about ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... , Sept. 28, 2017 Hill-Rom Holdings, ... 2017 earnings conference call and webcast on Friday, November ... a.m. (EDT) and ending at approximately 8:30 a.m. (CDT) ... discussing the company,s 2017 financial performance and guidance for ... opportunities, initiatives to enhance operational performance, and long-range financial ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
Breaking Medicine Technology: